Larimar Therapeutics, Inc.
LRMR
$3.44
-$0.06-1.71%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.19M | 4.85M | 4.67M | 4.52M | 4.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.12M | 64.02M | 49.50M | 27.79M | 31.19M |
| Operating Income | -31.12M | -64.02M | -49.50M | -27.79M | -31.19M |
| Income Before Tax | -29.61M | -62.50M | -47.71M | -26.18M | -29.28M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -29.61M | -62.50M | -47.71M | -26.18M | -29.28M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.61M | -62.50M | -47.71M | -26.18M | -29.28M |
| EBIT | -31.12M | -64.02M | -49.50M | -27.79M | -31.19M |
| EBITDA | -31.05M | -63.93M | -49.41M | -27.71M | -31.10M |
| EPS Basic | -0.33 | -0.73 | -0.61 | -0.41 | -0.46 |
| Normalized Basic EPS | -0.21 | -0.46 | -0.38 | -0.26 | -0.29 |
| EPS Diluted | -0.33 | -0.73 | -0.61 | -0.41 | -0.46 |
| Normalized Diluted EPS | -0.21 | -0.46 | -0.38 | -0.26 | -0.29 |
| Average Basic Shares Outstanding | 90.26M | 85.18M | 78.32M | 64.03M | 63.96M |
| Average Diluted Shares Outstanding | 90.26M | 85.18M | 78.32M | 64.03M | 63.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |